BUPIVACAINE
| Brand name | POSIMIR |
|---|---|
| Active ingredient | BUPIVACAINE |
| Strength | 660MG/5ML (132MG/ML) |
| Dosage form | SOLUTION |
| Route | INFILTRATION |
| Modality | Small molecule |
| FDA approval | February 2021 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 11771624 | January 2041 | use U-3724 |
| 11400019 | January 2041 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.